Background: Persistent significant tricuspid regurgitation (TR) after successful left-sided valve surgery is frequently reported. Objectives: To evaluate the incidence, risk factors and clinical ...

The final Medicare coverage memo for transcatheter edge-to-edge repair for tricuspid valve regurgitation largely replicates the April 2025 draft, but cardiology centers will not have to bring an ...

CroíValve, a pioneering medical device company innovating a better way to help more patients suffering from Tricuspid ...

The results suggest minimal health status benefits once TR has dropped by three grades, but further research is needed.

The findings highlight the importance of having an EP versed in lead management on the heart valve team, one expert says.

Major limitations of the study include its observational nature and small sample, Ninios cautioned.

Background Although the presence of an RV lead is a potential cause of tricuspid regurgitation (TR), the clinical impact of significant lead-induced TR is unknown. Objective To evaluate the effect of ...

Edwards Lifesciences Corporation today announced the company's EVOQUE tricuspid valve replacement system has received Health ...

For the estimated 1.6 million Americans diagnosed with symptomatic tricuspid valve regurgitation each year, a significant ...

Also known as "Nimbus," the new COVID variant NB.1.8.1 is characterized by its extremely painful sore throat, described as "razor blade throat." ...

To determine the impact of tricuspid regurgitation (TR) on outcomes after transcatheter aortic valve implantation (TAVI), and to determine the evolution of TR severity after TAVI. This was an ...